Structure Therapeutics, Inc. Sponsored ADR ( (GPCR) ) has released its Q3 earnings. Here is a breakdown of the information Structure ...

“We are in a period of great momentum and execution at Structure Therapeutics (GPCR), having begun ... profile of GSBR-1290 as a potential best-in-class oral small molecule GLP-1 receptor agonist. We ...

Thank you for standing by. My name is John, and I’ll be your conference operator today. At this time I would like to welcome everyone to the Allurion Third Quarter Earnings Call. All lines have been ...

Allurion Technologies Inc (ALUR) reports significant growth in recurring revenue and strategic restructuring, despite facing market headwinds and product recalls.

US equities overcame brief spells of volatility to reach new all-time highs in Q3 as underlying earnings growth remained positive. Read more here.

They came of age without fillers or selfies, now they’re approaching aesthetic interventions in their own unique way.

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

As Ozempic and other GLP-1 drugs explode in popularity, driven by their off-label use for rapid weight loss and viral social media trends, the pharmaceutical industry faces unprecedented challenges.

Citrin Cooperman announced today that it has entered into an agreement to acquire substantially all the assets of Clearview Group, a Baltimore metro-based management consulting and CPA firm. This ...